Biotechnology

Bluebird Bio

Meta/Facebook

Appraisal value

Hot topic

00700

TCEHY

TCTZF

80700

CASH

BLUE

HTCD

These days, it's rare to see trillion-dollar giants fluctuating by 10% or 20% in a single day, but Meta is an exception. It took Meta just one quarter to fall from grace. After the Q3 earnings report, investors' panic seemed to have just been digested. Recently, with the expectation of interest rate cuts rising, $Meta Platforms(META.US) has rebounded 10% from the bottom. In terms of narrative, first, Meta has the most extensive application scenarios, and the AI investment process will be accompanied by accelerated revenue, the &#34;AI darling&#34; narrative; then came the Q3 combination of increased investment and slowed revenue growth guidance...

Meta Platforms

TENCENT

Blue Owl Capital

Tencent

Tencent Holdings Limited

TENCENT-R

Pathward Fin

Tencent HK SDR 10to1

"AI Darling" Quickly Becomes a "Spendthrift", Can Meta Make a Comeback?

NVIDIA

Conference Minutes

OpenAI

NVDA

AVGO

DXYZ

NOA3

ORCL

AMDL

NVDL

07788

07388

NVDY

NVDD

NVDX

NVDQ

OPEN

BEAT

IONQ

OPENL

OPENW

OPENZ

BEATW

1. Key Points of the GTC Conference 1. NVIDIA has established a strategic partnership with Nokia, investing $1 billion in Nokia's equity. They released a new product series called 'NVIDIA ARC,' which Nokia will use for future base stations to upgrade 6G and AI capabilities; 2. They released the NVQLink interconnect architecture and the CUDAQ platform, which directly connects GPU supercomputers with QPUs (quantum processors), laying the groundwork for quantum computing processors; 3. $NVIDIA(NVDA.US) is collaborating with the U.S. Department of Energy to build the largest AI supercomputer in the United States...

Broadcom

Destiny Tech100

Nokia Oyj

Nokia

Oracle

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

Direxion Daily NVDA Bear 1X ETF

T-Rex 2X Long NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

Opendoor Tech

HeartBeam

IonQ

Opendoor Tech Series A - CW26

Opendoor Tech Series K - CW26

Opendoor Tech Series Z - CW26

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

 GTC Conference: Next Year's Shipment 'Blockbuster', is NVIDIA‘s Limit Really “Sky”？

Bluebird Bio Updates Merger Agreement Offering $5 Per Share

Bluebird Bio released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 38.71 M (forecast USD 37.63 M), actual EPS USD -2.9811 (forecast USD -3.508)

Bluebird Exceeds Earnings Expectations in Q1 2025

Bluebird Bio Receives $5 Per Share Acquisition Offer

Bluebird Bio Sees 104.1% Quarterly Revenue Growth

US Stock Index Futures Decline Due to Tariff Policy Concerns, Related Stock Movements Fluctuate

Bluebird Bio's stock price rises 10% due to Ayrmid's acquisition offer

Bluebird Bio Receives Informal Proposal from AYRMID at $4.50 per Share

Bluebird Bio released FY2024 annual earnings on March 27 (EST), actual revenue $83.81M (forecast $73.23M), actual EPS -$24.8441 (forecast -$30.2328)

Bluebird Bio released FY2024 Q4 earnings on March 27 (EST), actual revenue 38.52 M USD (forecast 27.07 M USD), actual EPS -2.9545 USD (forecast -5.8715 USD)

bluebird bio announces 1-for-20 reverse stock split

Bluebird Bio Participates in CMMI Cell and Gene Therapy Access Model, Agreement Deadline by February 28, 2025

FDA Considers Regulatory Action on bluebird bio's Gene Therapy

Bluebird Bio released FY2024 9 Months Earnings on November 14 Pre-Market EST, with actual revenue of USD 45.29 M and EPS of USD -21.9056

Bluebird Bio released FY2024 Q3 earnings on November 14 Pre-Market (EST), actual revenue $10.61M (forecast $18.68M), actual EPS -6.2723 (forecast -0.3687)

Bluebird Bio to Release FY2024 Q3 Earnings on November 14, Pre-Market EST; Forecasted Revenue: 18.68 M USD, EPS: -7.375 USD

Bluebird Bio released FY2024 Q2 earnings on September 27 Pre-Market EST, actual revenue $16.10M (forecast $23.23M), actual EPS -8.4033 (forecast -0.3592)

Bluebird Bio released its FY2024 Semi-Annual Earnings on September 27 Pre-Market (EST), with actual revenue of 34,674,000 USD and an EPS of -15.633

Bluebird Bio's Q4 2025 Earnings Forecast and Price Target Adjustments

Bluebird Bio Launches Restructuring Plan

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap